TRICARE and the Fight for Military Pharmacy Access | PBM Reform with APCI

The PBM Reform Podcast, sponsored by APCI, welcomes John Vinson, PharmD, Chief Executive Officer of the Arkansas Pharmacists Association, for a timely conversation with host Greg Reybold about the management of the TRICARE pharmacy benefit.

Express Scripts administers pharmacy benefits for TRICARE, the Department of Defense healthcare program serving more than 9 million active-duty service members, military retirees, and family members. In fiscal year 2023 alone, TRICARE spent more than $8 billion on prescription medications.

Greg and John examine concerns surrounding Express Scripts’ administration of the program, including shrinking pharmacy networks, reduced patient choice, questionable contractor reporting, specialty-drug delivery oversight, and the consequences for independent and rural pharmacies.

A 2025 Government Accountability Office investigation found that:

TRICARE’s minimum network requirement fell from 50,000 to 35,000 pharmacies.

The network had approximately 13,165 fewer pharmacies in late 2024 than in late 2022.

An estimated 380,000 beneficiaries may have been forced to find another pharmacy.

The Defense Health Agency relied heavily on contractor-submitted reports that contained inaccuracies.

DHA had not consistently audited the data used to evaluate beneficiary access.

GAO’s two corrective recommendations remain open as of August 2026, although DHA has begun adding reporting and auditing requirements.

The episode also addresses higher 2026 prescription copayments. For most non-active-duty beneficiaries, home-delivery copays are now $14 for generic formulary drugs, $44 for brand-name drugs, and $85 for non-formulary medications. At retail network pharmacies, the corresponding 30-day copays are $16, $48, and $85.

Greg and John discuss whether PBM-driven network reductions represent true savings—or simply transfer costs, inconvenience, and access barriers to military families and the community pharmacies serving them.